Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 30

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
Neuropeptide Y (NPY) is a 36-amino acid neurotransmitter and neuromodulator widely distributed in the mammalian central and peripheral nervous system and has been associated with a number of physiological and pathological conditions. In the forebrain this peptide is preferentially expressed in interneurons and modulates, mainly inhibits, the release of other neurotransmitters. NPY acts on specific receptors coupled to G-proteins, and 6 types of NPY receptors (Y1 to Y6) have been identified based on different pharmacological profiles. It has been well documented that NPY inhibits glutamatergic transmission and decreases hippocampal epileptiform activity which may lead to neuroprotection. Our earlier studies demonstrated the neuroprotective activity of NPY injected into the hippocampus on kainate neurotoxicity in that structure. The neuroprotective action of NPY against excitotoxicity was also shown in neuronal cultures. Studies with specific Y receptor ligands revealed a crucial role of Y2 and Y5 receptors. Activation of those receptors diminished neuronal excitotoxic degenerations both in vitro and in vivo, but no protective effect was observed after Y1 agonist. One of the most promising finding of our study is that NPY or Y2 and Y5 ligands exert a significant neuroprotective effect after delayed treatment, 3 – 6 h after the onset of intoxication. Much less in known about the protective action of NPY on ischemic damage, both in vitro and in vivo, but some positive effects were also found. The role of NPY in chronic neurodegenerations such as Alzheimer, Parkinson and Huntington diseases has also been postulated but the results are divergent and unclear. Summing up, our data and other authors studies indicate the neuroprotective properties of NPY; moreover, the effectiveness of delayed treatment may open up a future possibility of the potential therapeutic use of such compounds in patients.
5
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Astrocyty a depresja

63%
6
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Ignacy Domeyko 1802-1889

63%
7
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Astrocyty a intelekt

63%
Postmortem studies of depressed patients showed that one of the most consistent findings is a decrease in the density of glial cells in human brain cortical regions, especially in the prefrontal and cingular areas. Furthermore, a decline in the number of astrocytes in the prefrontal cortex was found in rats after chronic unpredictable stress – one of the generally accepted animal models of depression. An important function of astrocytes in the brain tripartite synapse is the uptake of released glutamate. Hence the basic consequence of the loss of astrocytes is a reduction in glutamate uptake and an excess of glutamate in the synaptic cleft. The glutamatergic predominance in the excitator-inhibitory balance is postulated to be involved in the pathogenesis of depression. Recently, depressive-like behavior have been demonstrated in rats after astrocytes ablation. Therefore in the present study we tried to ascertain whether astroglial degeneration in the prefrontal cortex was sufficient to induce a depressive-like behavior and could serve as an animal model of depression. Astrocytic toxin L- or D,Lalpha-aminoadipic acid (AAA), 100 µg/2 µl, was microinjected bilaterally into rat medial prefrontal cortex (PFC). The toxins were injected twice, on day 1 and 2; afterwords depressive-like behavior was assessed by a forced swim test on day 5 of the experiment. Some rats were additionally treated with the antidepressant imipramine (30 mg/kg, i.p.) 24, 5 and 1 h before the forced swim test. The rats’ brains were taken out for an analysis on day eight. Histological verifications of the injection sites and immunohistochemical staining for the astrocytic marker glial fibrillary acidic protein (GFAP), were carried out. The GFAP positive cells were stereologically counted in the PFC. Also the level of GFAP expression was determined by the Western blot analysis in all the experimental groups. It was found that both L-AAA and DL-AAA induced a significant increase in immobility time in the forced swim test, without changing the overall locomotor activity, which indicates depressive-like effects of these compounds. The immunohistochemical and Western blot analyses showed a significant decrease in the number of GFAP-positive cells and GFAP level in the PFC of toxin-treated rats. The decrease amounted to ca. 50%. Both the behavioral and the GFAP changes were reversed or partially inhibited by imipramine injection. The obtained results suggest an important role of astrocytes in the PFC in mood regulation; moreover, they indicate that the degeneration of astrocytes in this structure may be used as an animal model of depression. This study was supported by Grant POIG.01.01.02-12-004/09Friday, November 23, 2012
Oxygen-glucose deprivation (OGD) induces excitotoxic cell death mediated primarily by excessive release of glutamate. A growing body of evidence suggests that metabotropic glutamate (mGlu) receptors can modulate glutamatergic transmission, so these receptors are regarded as potential targets for neuroprotective drugs. Group III mGluRs (mGlu4, mGlu6, mGlu7 and mGlu8) agonists are known to reduce glutamatergic neurotransmission by inhibiting glutamate release. Therefore in the present study we tried to find out whether the agonist of group III mGluR (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-1) and the first selective allosteric mGlu7 receptor agonist, N,N’-bis (diphenylmethyl)-1,2- ethanediamine (AMN082) have neuroprotective potential in primary neuronal cortical cultures exposed to oxygen-glucose deprivation, as an in vitro ischemic injury paradigm. In order to evoke toxic effects cortical cultures were exposed to OGD for 1 - 5 h. ACPT-1, at concentrations of 1, 10, 100 and 200 µM, or AMN082, at concentrations of 0.01, 0.1, 0.5 and 1 µM, were applied in two ways: twice, just before the start of OGD and immediately after OGD or once, immediately after OGD. Neurotoxicity was measured by lactate dehydrogenase (LDH) efflux from the damaged cells into the culture media 24 h after the end of OGD. It was found that a double application of ACPT-1 or AMN082 significantly attenuated the LDH release by 20-30% and 30-43%, respectively. A particularly important finding is that AMN082, given once after the end of OGD also significantly decreased ischemic-induced LDH release by 30%. These data were confirmed by immunohistochemical staining for the presence of characteristic neuronal protein MAP-2. In conclusion, the above results indicate that group III mGlu receptor agonists may have neuroprotective potential and may play a potential therapeutic role in neurodegenerative disorders. The study was supported by Grant No N N401 091037 from the MSHE, Poland.
Neuropeptide Y (NPY), a 36 amino acid neurotransmitter, is involved in the regulation of emotional behavior and its role in the central responses to peripheral immune challenge is postulated. Plasma NPY levels rises in human sepsis and NPY improved survival in the experimental endotoxic shock induced by lipopolysaccharide (LPS) injection. Some of the behavioral effects of LPS, anorexia, depression and anxiety-like behavior are also modulated by NPY. Therefore, in the present study tried to fi nd out if LPS affected NPY neurons in mouse hippocampus, a structure most susceptible to damage and involved in the regulation of emotion. Male C57BL/6 mice were injected with LPS (1 m/kg, i.p.) and their brains were taken after 6 or 24 h. The brains were fi xed with paraformaldehyde, cut into frontal sections containing the dorsal hippocampus and processed by immunohistochemistry using an NPY antibody. NPY-immunoreactive neurons were counted stereologically in hippocampal subregions CA1+2, CA3 and DG+hilus, and results were statistically analysed. It was found that after 24 h LPS decreased by ca. 38% the number of NPY-positive neurons in the hippocampal CA regions. The effect was particularly signifi cant in the CA3 area. Moreover, staining intensity was diminished. The obtained results indicate a decrease in NPY expression in the hippocampus, which may be due to the peptide release induced by LPS infl ammatory action. Supported by MS&HE.28/E32/ BWSN-0053/2008.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.